SCHEMBL7285152

SCHEMBL7285152

NCCCCN1CCN(c2nsc3ccccc23)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.67
HTR1A P08908 2/20 0.67
DRD2 P14416 1/20 0.67
HTR7 P34969 1/20 0.67
HTR6 P50406 1/20 0.67
ADRA1D P25100 2/20 0.65
ADRA1B P35368 2/20 0.65
LMNA P02545 1/20 0.64
CHRM2 P08172 1/20 0.64
ADRA2A P08913 1/20 0.64
CHRM1 P11229 1/20 0.64
DRD1 P21728 1/20 0.64
TBXA2R P21731 1/20 0.64
SLC6A2 P23975 1/20 0.64
SLC6A4 P31645 1/20 0.64
ADRA1A P35348 1/20 0.64
OPRM1 P35372 1/20 0.64
DRD3 P35462 1/20 0.64
SLC6A3 Q01959 1/20 0.64
KCNH2 Q12809 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792909 0.96 HTR2A (0.65) HTR2AHTR1ADRD2HTR7HTR6
Hydrochloric Acid SCHEMBL2215669 0.95 HTR2A (0.64) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL792872 0.91 HTR2A (0.66) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL10843227 0.87 HTR2A (0.67) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL25335774 0.86 HTR2A (0.67) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL30515499 0.86 HTR2A (0.67) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL9377388 0.86 HTR2A (0.58) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL8671981 0.85 HTR2A (0.65) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL6185115 0.85 HTR2A (0.65) HTR2AHTR1ADRD2HTR7HTR6
SCHEMBL7771353 0.85 HTR2A (0.65) HTR2AHTR1ADRD2HTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115707701-A High-purity perospirone and preparation method and application thereof 四川科瑞德制药股份有限公司 2023-02-21 CN disclosed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
EP-0511610-B1 Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments HOECHST ROUSSEL PHARMA (US) 1996-09-11 EP disclosed
EP-0687255-A1 QUINOLONE DERIVATIVES AS DOPAMINE D4 LIGANDS MERCK SHARP & DOHME LTD. (GB) 1995-12-20 EP disclosed
EP-0683778-A1 HETEROAROMATIC COMPOUNDS WITH ANTIPSYCHOTIC ACTIVITY THE WELLCOME FOUNDATION LIMITED (GB) 1995-11-29 EP disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
WO-1994020471-A1 QUINOLONE DERIVATIVES AS DOPAMINE D4 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1994-09-15 WO disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed
EP-0364091-B1 ANTIPSYCHOTIC 4-(4-(3-BENZISOTHIAZOLYL)-1-PIPERAZINYL)BUTYL BRIDGED BICYCLIC IMIDES PFIZER INC. (US) 1993-07-28 EP disclosed
US-5225412-A Antipsychotic HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-07-06 US disclosed
EP-0511610-A1 Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-11-04 EP disclosed
US-5143923-A Psychological disorders HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1992-09-01 US disclosed
EP-0196096-B1 IMIDE DERIVATIVES, THEIR PRODUCTION AND USE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1992-04-22 EP disclosed
US-4968792-A Psychotropic benzisothiazole derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1990-11-06 US disclosed
EP-0364091-A1 Antipsychotic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)butyl bridged bicyclic imides PFIZER INC. (US) 1990-04-18 EP disclosed
US-4745117-A NEUROLEPTIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1988-05-17 US disclosed
EP-0196096-A2 Imide derivatives, their production and use SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1986-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR2A 1150/4885HTR1A 1354/4885DRD2 3216/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR2A 1150/4885HTR1A 1354/4885DRD2 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.